Jain Akansha, Kuryatov Alexander, Wang Jingyi, Kamenecka Theodore M, Lindstrom Jon
From the Department of Neuroscience, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104.
the Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78712, and.
J Biol Chem. 2016 Nov 4;291(45):23452-23463. doi: 10.1074/jbc.M116.749150. Epub 2016 Sep 19.
All nicotinic acetylcholine receptors (nAChRs) evolved from homomeric nAChRs in which all five subunits are involved in forming acetylcholine (ACh) binding sites at their interfaces. Heteromeric α4β2* nAChRs typically have two ACh binding sites at α4/β2 interfaces and a fifth accessory subunit surrounding the central cation channel. β2 accessory subunits do not form ACh binding sites, but α4 accessory subunits do at the α4/α4 interface in (α4β2)α4 nAChRs. α5 and β3 are closely related subunits that had been thought to act only as accessory subunits and not take part in forming ACh binding sites. The effect of agonists at various subunit interfaces was determined by blocking homologous sites at these interfaces using the thioreactive agent 2-((trimethylammonium)ethyl) methanethiosulfonate (MTSET). We found that α5/α4 and β3/α4 interfaces formed ACh binding sites in (α4β2)α5 and (α4β2)β3 nAChRs. The α4/α5 interface in (β2α4)α5 nAChRs also formed an ACh binding site. Blocking of these sites with MTSET reduced the maximal ACh evoked responses of these nAChRs by 30-50%. However, site-selective agonists NS9283 (for the α4/α4 site) and sazetidine-A (for the α4/β2 site) did not act on the ACh sites formed by the α5/α4 or β3/α4 interfaces. This suggests that unorthodox sites formed by α5 and β3 subunits have unique ligand selectivity. Agonists or antagonists for these unorthodox sites might be selective and effective drugs for modulating nAChR function to treat nicotine addiction and other disorders.
所有烟碱型乙酰胆碱受体(nAChRs)均由同聚体nAChRs进化而来,其中所有五个亚基都参与在其界面处形成乙酰胆碱(ACh)结合位点。异聚体α4β2* nAChRs通常在α4/β2界面处有两个ACh结合位点,以及围绕中央阳离子通道的第五个辅助亚基。β2辅助亚基不形成ACh结合位点,但α4辅助亚基在(α4β2)α4 nAChRs的α4/α4界面处形成ACh结合位点。α5和β3是密切相关的亚基,一直被认为仅作为辅助亚基,不参与形成ACh结合位点。通过使用硫反应性试剂2-((三甲基铵)乙基)甲硫代磺酸盐(MTSET)阻断这些界面处的同源位点,来确定激动剂在各种亚基界面处的作用。我们发现α5/α4和β3/α4界面在(α4β2)α5和(α4β2)β3 nAChRs中形成ACh结合位点。(β2α4)α5 nAChRs中的α4/α5界面也形成了一个ACh结合位点。用MTSET阻断这些位点可使这些nAChRs的最大ACh诱发反应降低30-50%。然而,位点选择性激动剂NS9283(用于α4/α4位点)和沙扎替丁-A(用于α4/β2位点)对由α5/α4或β3/α4界面形成的ACh位点无作用。这表明由α5和β3亚基形成的非传统位点具有独特的配体选择性。针对这些非传统位点的激动剂或拮抗剂可能是调节nAChR功能以治疗尼古丁成瘾和其他疾病的选择性有效药物。